Pharmacokinetics and tissue distribution of Ginkgolide A (cas 15291-75-5), ginkgolide B, and ginkgolide K after intravenous infusion of ginkgo diterpene lactones in a rat model
-
Add time:08/03/2019 Source:sciencedirect.com
Ginkgo diterpene lactones are compounds that are extracted from the Ginkgo biloba leaf and possess pharmacologic activities with neuroprotective effects. To address the poor bioavailability of ginkgo diterpene lactones, ginkgo diterpene lactone meglumine injection (GDLI) was formulated and is commercially available. In this study, a simple, sensitive and reliable liquid chromatography-tandem mass spectrometry (LC–MS/MS) method was developed and validated for assessing the total amount and the amount of the prototype forms of ginkgolides A (GA), B (GB) and K (GK) in rat plasma and tissues. This method was used to calculate the concentrations of the hydrolysed carboxylic forms and assess the pharmacokinetics of the ginkgolides after intravenous (i.v.) GDLI administration in rats. Generally, all three ginkgolide forms showed dose-dependent plasma concentrations, and no obvious differences in pharmacokinetic parameters, i.e., area under the curve (AUC) of plasma concentration versus time and half-life, were observed after GDLI administration on 7 consecutive days. These ginkgolides primarily existed in the carboxylic form in the plasma, and the systemic concentrations of the carboxylic forms of GA and GB were 11- to 17- and 3- to 4-fold higher than those of their prototype forms, respectively. In contrast, dramatically increased levels of the GA and GB prototype lactones were detected in the liver and heart. GA, GB, and GK were extensively distributed in various organs/tissues; the highest levels were found in the kidneys, liver, and intestine, and the lowest levels were found in the brain. These data suggest that ginkgolides have difficulty crossing the blood–brain barrier and that their targets for protecting against cerebral ischaemia are located outside the central system.
We also recommend Trading Suppliers and Manufacturers of Ginkgolide A (cas 15291-75-5). Pls Click Website Link as below: cas 15291-75-5 suppliers
Prev:Experimental and theoretical studies on the thermal decomposition of 1,1,2,2,3,3,4-HEPTAFLUOROCYCLOPENTANE (cas 15290-77-4)
Next:Formulation and evaluation of gastric-floating controlled release tablets of Ginkgolides) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Ginkgolide A (cas 15291-75-5) ameliorates non-alcoholic fatty liver diseases on high fat diet mice08/10/2019
- Ginkgolides-loaded soybean phospholipid-stabilized nanosuspension with improved storage stability and in vivo bioavailability08/09/2019
- Pharmacokinetics of the prototype and hydrolyzed carboxylic forms of ginkgolides A, B, and K administered as a ginkgo diterpene lactones meglumine injection in beagle dogs08/08/2019
- Ginkgolide B functions as a determinant constituent of Ginkgolides in alleviating lipopolysaccharide-induced lung injury08/07/2019
- Ginkgolide C reduced oleic acid-induced lipid accumulation in HepG2 cells08/06/2019
- Characterizations of the hydrolyzed products of Ginkgolide A (cas 15291-75-5) and ginkgolide B by liquid chromatography coupled with mass spectrometry08/05/2019
- Formulation and evaluation of gastric-floating controlled release tablets of Ginkgolides08/04/2019
-
Health and Chemical more >
-
Related Products